- Tebipenem pivoxil
-
-
2026-07-03
- CAS:161715-24-8
- Min. Order: 10g
- Purity: 99%min
- Supply Ability: 10kg
- Tebipenem Pivoxil
-
- $30.00
-
2026-04-22
- CAS:161715-24-8
- Purity: 99.32%
- Supply Ability: 10g
|
| | TEBIPENEM PIVOXIL Basic information |
| Product Name: | TEBIPENEM PIVOXIL | | Synonyms: | (1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester;Tebipenem Pivoxil;[(2,2-Dimethylpropanoyl)oxy]methyl (4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;(4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid (2,2-DiMethyl-1-oxopropoxy)Methyl Ester;[4R-[4α,5β,6β(R*)]]-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-Methyl-7-oxo-1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid (2,2-DiMethyl-1-oxopropoxy)Methyl Ester;OrapeneM;ME1211;TBPM-PI | | CAS: | 161715-24-8 | | MF: | C22H31N3O6S2 | | MW: | 497.63 | | EINECS: | 1308068-626-2 | | Product Categories: | Inhibitors;API | | Mol File: | 161715-24-8.mol |  |
| | TEBIPENEM PIVOXIL Chemical Properties |
| Melting point | 140-142℃ | | Boiling point | 661.9±65.0 °C(Predicted) | | density | 1.50 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | | pka | 14.36±0.20(Predicted) | | form | Solid | | color | White | | InChIKey | SNUDIPVBUUXCDG-QHSBEEBCSA-N | | SMILES | N12[C@@]([H])([C@@H]([C@H](O)C)C1=O)[C@@H](C)C(SC1CN(C3=NCCS3)C1)=C2C(OCOC(=O)C(C)(C)C)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | TEBIPENEM PIVOXIL Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | Tebipenem Pivoxil is an oral carbapenem antibiotic. Tebipenem Pivoxil is absorbed and metabolized into Tebipenem, its active metabolite which showed excellent bactericidal activity against β-lactamase-nonproducing, ampicillin-resistant isolates. | | Uses | Tebipenem pivoxil(L-084) is a novel oral carbapenem antibiotic with an IC50 of 100 μg/ml for human CYP isoforms. In mouse, rat, dog and monkey, TBPM-PI were absorbed quickly, and the bioavailability was (71.4, 59.1, 34.8 and 44.9%, respectively. There was | | Definition | ChEBI: Tebipenem pivoxil is a member of carbapenems and a pivaloyloxymethyl ester. | | Biological Activity | Tebipenem pivoxil (L-084I; ME1211; SPR994; Tebi-pivoxil; TBM-PI) corresponds to the orally bioavailable pivalyl ester prodrug form of the carbapenem class broad-spectrum β-lactam antibiotic Tebipenem (LJC 11,036; SPR859; TBM). TBM is potent against both gram-positive and gram-negative bacteria, including penicillin-resistant S. pneumoniae (PRSP) and many β-lactamase-producing strains, while being less effective against methicillin-resistant S. aureus (MRSA), S. marcescens, and P. aeruginosa. TBM is 2- to 64-fold more potent than imipenem, cefdinir, and faropenem against clinical isolates from respiratory and urinary-tract infections. | | in vivo | Tebipenem pivoxil (L084) (0-4.00 g/kg; p.o.; once) shows minimal lethal dosage (MLD) of 4.00 g/kg and the maximum tolerance dosage (MTD) of 3.40 g/kg in mice[1].
Tebipenem pivoxil (50 and 100 mg/kg; p.o.; once) significantly protects the sepsis mice challenged with various pathogenic bacteria[1]. | Animal Model: | KM mice weighing 18–22 g[1] | | Dosage: | 2.89, 3.40 and 4.00 g/kg | | Administration: | Oral administration (tablet), once | | Result: | Within the 14-day observation period, only one mouse was dead in the maximum oral dosage (4.00 g/kg). The minimal lethal dosage (MLD) was 4.00 g/kg and the maximum tolerance dosage (MTD) in the mice was 3.40 g/kg. Showed dose-dependent liver and kidney damage. |
| Animal Model: | ICR mice, sepsis mouse models[1] | | Dosage: | 50 and 100 mg/kg | | Administration: | Oral administration (tablet), once | | Result: | Significantly increased the survival number of the sepsis mice within a 168 h observation period. |
| | IC 50 | β-lactam |
| | TEBIPENEM PIVOXIL Preparation Products And Raw materials |
|